Evidence / Poulsen et al. · 2013
A resveratrol trial with a null insulin-sensitivity result
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind, placebo-controlled parallel trial.
- Product relevance
- Ingredient evidence from a separate resveratrol intervention.
- Sample or population
- 24 men with obesity who were otherwise healthy.
- Studied dose
- The abstract describes high-dose resveratrol and does not report the amount.
- Duration
- 4 weeks.
- Finding
- The study found no improvement in its primary insulin-sensitivity outcome or in the reported blood pressure, energy expenditure, fat or biomarker measures.
- Limitations
- A short study in a selected population cannot establish outcomes for other preparations or longer use.
- Study quality
- Prespecified primary outcome measured using a glucose clamp. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.